Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant

1 Key Laboratory of Combined Multi-Organ Transplantation Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University. Hangzhou 310003, China
2 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University. Hangzhou 310003, China

These authors contributed to this work equally

Special Issues: Advanced Big Data Analysis for Precision Medicine

Objective: To compare the 2-year efficacy and safety of combination therapy with entecavir (ETV) and adefovir dipivoxil (ADV) to that of tenofovir disoproxil fumarate (TDF) monotherapy in treatment of patients with adefovir drug-resistant chronic hepatitis B. Methods: HBeAg-positive CHB patients (n = 100) with adefovir-resistance (rtA181T/V and/or rtN236T) were enrolled. Patients were treated with either ETV 0.5 mg plus ADV 10 mg per day (n = 52) or TDF 300 mg per day (n = 48) for 48 weeks. Tests for liver and kidney function, Serum Phosphorus, HBV serum markers, HBV DNA load and ultrasonography of liver were performed every 3 months. Student's t-test and χ2 test were used to compare the efficacy, side effects in the two groups. Results: Fifty-two patients in ETV + ADV group and forty-eight patients in TDF group were followed-up for 96 weeks. HBV DNA undetectable rate were 76.9% versus 81.3% (P = 0.631) at week 48, and 92.3% versus 95.8% (P = 0.679) at week 96 in ETV + ADV combination therapy and TDF monotherapy group respectively. Serum ALT normalized rate were 84.6% versus 87.5% (P = 0.777) at week 48, and 92.3% versus 95.8% (P = 0.679) at week 96 in ETV+ADV combination therapy and TDF monotherapy group respectively. But the level of serum Phosphorus was significantly lower in ETV + ADV combination therapy group compare with TDF monotherapy group (1.13 ±0.15 versus 1.22 ±0.16, P = 0.004) at week 96. Conclusion: Both ETV + ADV combination therapy and TDF monotherapy provided effective treatments in chronic hepatitis B with adefovir-resistant. However, it was associated with poor serological responses up to week 96. The long term treatment of hepatitis B with ETV (0.5 mg/day) combination of ADV (10 mg/day) can potentially cause hypophosphatemia and renal impairment, so regular monitoring of serum phosphate, serum creatinine and evaluation of eGFR is needed.
  Figure/Table
  Supplementary
  Article Metrics

Keywords chronic hepatitis B; adefovir-resistant; adefovir dipivoxil; entecavir; tenofovir disoproxil fumarate; combination therapy; hypophosphatemia

Citation: Ming-Chun Lai, Jiang-Shan Lian, Wen-Jin Zhang, Jun Xu, Lin Zhou, Shu-Sen Zheng. Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant. Mathematical Biosciences and Engineering, 2020, 17(1): 627-635. doi: 10.3934/mbe.2020032

References

  • 1. J. J. Ott, G. A. Stevens, J. Groeger, et al., Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity, Vaccine, 30 (2012); 2212-2219.
  • 2. U. H. Iloeje, H. I. Yang, J. Su, et al., Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130 (2006), 678-686.
  • 3. G. A. Kim, Y. S. Lim, S. Han, et al., High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B, Gut, 67 (2018), 945-952.
  • 4. M. Aizawa, A. Tsubota, K. Fujise, et al., Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients, J. Med. Virol., 83 (2011), 953-961.
  • 5. R. P. Perrillo, H. W. Hann, E. Schiff, et al., Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance, Hepatol. Int., 5 (2011), 654-663.    
  • 6. N. A. Terrault, N. H. Bzowej, K. M. Chang, et al., AASLD guidelines for treatment of chronic hepatitis B, Hepatology, 63 (2016), 261-283.
  • 7. C. L. Lai, J. Dienstag, E. Schiff, et al., Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B, Clin. Infect. Dis., 36 (2003), 687-696.
  • 8. W. Ke, L. Liu, C. Zhang, et al., Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: A systematic review and meta-analysis, PLoS One, 9 (2014), e98865.
  • 9. F. Güzelbulut, A. O. Ovünç, Z. A. Oetinkaya, et al., Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B, Hepatogastroenterology, 59 (2012), 477-480.
  • 10. Z. B. Huang, S. S. Zhao, Y. Huang, et al., Comparison of the Efficacy of Lamivudine Plus Adefovir Versus Entecavir in the Treatment of Lamivudine-Resistant Chronic Hepatitis B: A Systematic Review and Meta-Analysis, Clin. Ther., 35 (2013), 1997-2006.
  • 11. A. S. Lok, B. J. McMahon, R. S. Brown, et al., Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis, Hepatology, 63 (2016), 284-306.
  • 12. W. K. Seto, Y. F. Lam, J. Fung, et al., Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment, J. Gastroenterol. Hepatol., 29 (2014), 1028-1034.
  • 13. M. Buti, N. Tsai, J. Petersen, et al., Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection, Dig. Dis. Sci., 60 (2015), 1457-1464.
  • 14. Y. F. Liaw, I. S. Sheen, C. M. Lee, et al., Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, Hepatology, 53 (2011), 62-72.    
  • 15. T. G. Vassiliadis, O. Giouleme, G. Koumerkeridis, et al., Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: A 4-year study, J. Gastroenterol. Hepatol., 25 (2010), 54-60.
  • 16. M. Tanaka, F. Suzuki, Y. Seko, et al., Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B, J. Gastroenterol., 49 (2014), 470-480.
  • 17. M. L. Chang and Y. F. Liaw, Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management, J. Hepatol., 61 (2014), 1407-1417.
  • 18. P. Thurairajah, A. Khanna and D. Mutimer, Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus (J. Viral. Hepat. 2010 Feb 1;17(2):123-9), J. Viral. Hepat., 18 (2011), 810-820.
  • 19. Y. J. Kim, H. C. Cho, D. H. Sinn, et al., Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients, J. Gastroenterol. Hepatol., 27 (2012), 306-312.

 

Reader Comments

your name: *   your email: *  

© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved